Niaid VRC

Ended Awarded Last action

Contract number
75N91020F00006
Awardee
Awarding agency
Obligated
$121,524,202

Award facts

Contract value 97% obligated
$125,779,921.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Funding agency
National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21702, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00016 · FY26 UDO initiative -$361
Other Administrative Action P00015 $882,401
Other Administrative Action P00014 $6,000,000
Other Administrative Action P00013 $0
Other Administrative Action P00012 $27,289,181
Other Administrative Action P00011 $1,623,831
Other Administrative Action P00010 $1,023,492
Other Administrative Action P00009 $5,919,518
Other Administrative Action P00008 $7,000,000
Other Administrative Action P00007 $19,483,497
Other Administrative Action P00006 $3,100,000
Other Administrative Action P00005 · Niaid VRC operational task order; covid: VRC is engaged in evaluating mrna vaccines for different variants in animal models so that an effective mrna vaccine is… $0
Exercise an Option P00004 $23,062,855
Other Administrative Action P00003 · Niaid vaccine research center (VRC) $0
Other Administrative Action P00002 $3,664,336
Other Administrative Action P00001 $500,000
Original award $21,975,452
Show all 17

About this award

Written by GovTribe AI ·

The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on August 31, 2020, with a ceiling value of $125.8 million under a cost-plus-fixed-fee pricing structure. The order supports the NIAID VRC FY26 UDO Initiative and was originally scheduled for completion on August 30, 2024.

Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center contractor and subsidiary of Leidos Holdings, Inc. Place of performance is Frederick, MD.

Service Contract Inventory reporting shows actual government-invoiced labor across fiscal years. FY2024 (the most recent reported year) reflected $26.9 million invoiced, 96.0 FTEs, and 199,803 contractor hours. The derived government-paid blended hourly rate declined across the reporting period, from $153.33/hr in FY2021 to $134.72/hr in FY2024. FY2021 through FY2024 show a steady increase in staffing from 68.1 FTEs to 96.0 FTEs and contractor hours from 141,605 to 199,803. Subcontracting depth remained minimal in FY2024, with four subcontractors accounting for 2 percent of total contractor hours.

Quick answers

Who was awarded contract 75N91020F00006?

75N91020F00006 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on August 31, 2020.

How much is contract 75N91020F00006 worth?

The government has obligated $121,524,202 on 75N91020F00006. Its current value, with exercised options, is $125,779,921.

Which agency awarded contract 75N91020F00006?

National Cancer Institute (National Institutes of Health) awarded 75N91020F00006, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).

Is contract 75N91020F00006 an order under another contract?

Yes. 75N91020F00006 is a delivery order under 75N91019D00024, an indefinite delivery contract.

Was contract 75N91020F00006 competed?

The extent of competition for 75N91020F00006 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login